CN108452291A - The method for treating ulcerative colitis with natural sericin - Google Patents
The method for treating ulcerative colitis with natural sericin Download PDFInfo
- Publication number
- CN108452291A CN108452291A CN201810721564.2A CN201810721564A CN108452291A CN 108452291 A CN108452291 A CN 108452291A CN 201810721564 A CN201810721564 A CN 201810721564A CN 108452291 A CN108452291 A CN 108452291A
- Authority
- CN
- China
- Prior art keywords
- sericin
- ulcerative colitis
- sodium alginate
- natural
- treating ulcerative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses natural sericins to treat ulcerative colitis（Ulcerative colitis,UC）Method.This method mainly prepares sericin by high temperature alkali dissolution method, by sericin/sodium alginate soln/CaCl2•2H2O solution mixing systems are standby at the silk gum treated for UC/sodium alginate composite hydrogel oral preparation, give intragastric administration on mice.Currently without using sericin not reported in terms of UC treatments, therefore the invention has convincingly demonstrated sericin has good application prospect in terms of UC oral medications.
Description
Technical field
The present invention relates to the fields such as pharmacy, pharmacology and Bio-Nano-Materials, and in particular to sericin treats ulcer
The method of property colitis.
Background technology
Silk is secreted silk liquid concretionary continuous fiber when matured silkworm cocoons, is a natural fiber albumen.It is main
To contain fibroin albumen and sericin.Compared with fibroin albumen, sericin has the amino acid composition of different and divides
Son amount distribution, thus larger difference is showed in structure, form, mechanical property and biology performance etc..Compared to silk
Fibroin, the mechanical performance of sericin is poor, degradation is very fast, thus in one section of very long period people to its attention degree
Far below the fibroin of silk internal layer.In silk goods industry, silk gum is often taken as waste, is discharged with waste water, and then is led
Cause it that effective development and utilization is not yet received.Since 2000, recover one's original simplicity, the back to nature green revolution is advocated,
Silk has been to be concerned by more and more people and pursues.
The sericin for accounting for silk total amount 20 ~ 30%, by feat of its abundant functional group, it is good it is water-soluble, nontoxic,
Good biocompatibility, promote the performances such as cell adhesion and proliferation activity, anti-oxidant and tyrosinase inhibitory action, gradually at
For the research hotspot of natural new material and field of medicaments.Lei et al.（ACS Appl. Mater. Interfaces 2016,
8, 6577−6585）It is prepared for the multi-functional silk gum nano-particle of load adriamycin for having cancer target folacin coupled, especially
It is applicable in and treats the cancer with high level expression folacin receptor by delivering hydrophobicity chemotherapeutics.Ayumu et al.（Int. J. Pharm.2011, 407,44-52）Silk gum is made biodegradable silk gum film, gel and sponge, albumen in controllable silk gum
The sustained release of matter.Zhaorigetu et al.（Biosci. Biotechnol. Biochem. 2001, 65, 2181-
2186）It was found that sericin inhibits the mouse Colon that 1,2- dimethylhydrazines are handled swollen by reducing oxidative stress and cell Proliferation
The generation of tumor.Aramwit et al.（Arch. Dermatol. Res.2013,305, 585-594.）Confirm that sericin can promote
Into the healing of the open surface of a wound, but in clinical studies, the application of silk gum is restricted, and also proves that sericin is being burnt for the first time
Hinder in Wound treating is safely and effectively.Thitikan et al.（Int. J. Biol. Macromol. 2015, 80, 636-
643）It is prepared for sodium alginate nanoparticles of load sericin, sodium alginate nanoparticles of the sericin load of preparation
It is further configured to surface gel, gel preparation is stable, the sea of topical application sericin load under acceleration conditions
Sodium alginate gel preparation can reach the inhibition of inflammation of carragheen induction.
Ulcerative colitis（Ulcerative colitis, UC）It is a kind of chronic recurrent idiopathic disease, feature
It is that colonic epithelium barrier is impaired and inflammation stable state is destroyed.The incidence of UC increases increasingly in recent years, and it is intractable to have been cited as the world
Disease.It is extremely difficult to cure UC completely at present, is still based on anti-inflammatory and adjusting immune response, so the purpose for the treatment of is slow
Inflammation is solved, the recurrent exerbation of inflammation is inhibited and promotes Mucous rehabilitation.The existing drug for treating UC：Such as aminosalicylic acids
Salazosulfadimidine and 5-aminosalicylic acid；Hydrocortisone, prednisone, the dexamethasone of glucocorticoids；Biological inhibition
The imuran of agent class, ciclosporin A；Also gradually applied to UC non-steroidal anti-inflammatory drugs curcumins treated etc..These drugs because
Its side effect is larger, expensive, water-soluble bad or bioavilability is low etc. limits its application.Current research mainly collects
In finding in terms of preparation process is simple, good biocompatibility, bioavilability are high and cheap drug.
Sericin applies no relevant report, the present invention to provide sericin treatment UC's for the first time in terms of UC treatments
Method contributes to us to carry out further research and exploitation to silk gum, there is prodigious economic and clinical conversion meaning.
Invention content
In consideration of it, treating UC using the sericin extracted from natural silk the purpose of the present invention is to provide a kind of
Method, sericin show preferably treat UC effect.
Technical scheme of the present invention is specific as follows：
1. the method for treating ulcerative colitis with natural sericin, which is characterized in that include the following steps：
（1）Sericin is extracted with the method for high temperature alkaline degradation, after purification, freeze-drying obtains sericin；
（2）It will（1）Obtained sericin/sodium alginate soln/CaCl2•2H2Silk gum/the sea treated for UC is made in O solution
Mosanom composite hydrogel；
（3）It will（2）Obtained silk gum/sodium alginate composite hydrogel suffers from the progress gavage processing of UC mouse to oral, for UC's
Treatment.
Further, the step（1）The molecular weight of middle sericin is more than 1 KDa.
Preferably, the step（1）The molecular weight of middle sericin is the KDa of 1 KDa ~ 220.
Further, the step（2）The quality of the sericin and sodium alginate of middle silk gum/sodium alginate composite hydrogel
Than being 1 ~ 50, ion crosslinking agent CaCl2•2H2A concentration of 1 ~ 5 wt% of O solution.
Preferably, by the step（2）The matter of the sericin and sodium alginate of middle silk gum/sodium alginate composite hydrogel
Amount is than being 100:（10~50）, ion crosslinking agent CaCl2•2H2A concentration of 1 ~ 2 wt% of O solution.
Further, the step（3）In Mouse oral sericin dosage be 0.1 ~ 5 g/kg.
Preferably, by the step（3）In Mouse oral sericin dosage be 0.5 g/kg.
Compared with the prior art, the advantage of the invention is that：
（1）The natural sericin utilized in the present invention is extracted from silk, and materials are simple and of low cost.
（2）The present invention is by by sericin/sodium alginate soln/CaCl2•2H2O solution is made answers for what UC was treated
Heshui gel carries out gavage to mouse, achieves the effect of good treatment UC.
（3）The method that the present invention provides sericin treatment UC for the first time.For current sericin in terms of UC treatments
Using the extensive concern for not causing scientific research personnel and pharmaceuticals, proposition of the invention can contribute to us and be carried out to silk gum
Further research and exploitation have prodigious economic and clinical conversion meaning.
Description of the drawings
To make the objectives, technical solutions, and advantages of the present invention clearer, below in conjunction with attached drawing to the present invention make into
The detailed description of one step, wherein：
Fig. 1, Fig. 2, Fig. 3 and Fig. 4 are natural sericin in the embodiment of the present invention 1 to the therapeutic effect figure of UC.
Specific implementation mode
Hereinafter reference will be made to the drawings, and the preferred embodiment of the present invention is described in detail, but is not limited to the present invention
Range.
Embodiment 1
（1）Silk gum is extracted with the method for high temperature alkaline degradation, after purification, it is the KDa's of 1 KDa ~ 220 that freeze-drying, which obtains molecular weight,
Sericin；
（2）It will（1）Obtained sericin/sodium alginate soln/CaCl2•2H2O solution mixing systems must be used for the silk of UC treatments
The mass ratio of glue/sodium alginate composite hydrogel, wherein sericin and sodium alginate is 33:7, ion crosslinking agent CaCl2•
2H21.04 wt% of concentration of O；
（3）It will（2）Obtained silk gum/sodium alginate composite hydrogel is to taking orally administration group（Sericin oral dose：0.5 g/
Kg, sericin weight/mouse weight）Mouse carries out gavage processing, is used for the treatment of UC.
Experiment 1：Mouse is divided into 3 groups, respectively healthy group, dextran sulfate sodium salt（dextran sulfate sodium,
DSS）Processing group, oral medication group（Sericin oral dose：0.5 g/kg, sericin weight/mouse weight）, first
The induction of mouse UC models is carried out, healthy group is drunk drinking water, and DSS processing group, oral medication group freely drink 3.5% DSS
Solution.Composite hydrogel is made in natural sericin and sodium alginate.It is small to oral administration group daily since DSS processing
Mouse carries out gavage processing, and health group and DSS processing groups use phosphate buffered saline solution daily（phosphate buffer saline,
PBS）Gavage, as a contrast.When DSS processing group mouse weights decline 10% or so, according to healthy group, DSS processing group and oral
The sequence of administration group dissects mouse, takes its colon, measures length, weighs；Its spleen is taken, is weighed, numerical value is recorded.
Shown in Fig. 1, ascendant trend is presented always in health group mouse weight, and DSS processing group mouse weight fall off rates are most fast,
Weight of the mouse weight of oral medication group close to health group mouse；
Fig. 2 is separate groups of mice colon lengths figure, and the mouse Colon length of DSS processing groups obviously shortens, oral medication group it is small
Colon lengths of the colon lengths of mouse close to health group mouse；
Fig. 3 is separate groups of mice colon weight figure, and the mouse Colon weight of DSS processing groups is substantially reduced, oral medication group it is small
Colon weight of the colon weight of mouse close to health group mouse；
Fig. 4 is the spleen weight figure of separate groups of mice, and the mouse spleen weight of DSS processing groups significantly increases, oral medication group
Spleen weight of the spleen weight of mouse close to health group mouse；In a word tomorrow, right sericin had well the treatment of UC
Effect.
Finally illustrate, the above examples are only used to illustrate the technical scheme of the present invention and are not limiting, although passing through ginseng
According to the preferred embodiment of the present invention, invention has been described, but it will be understood by those of ordinary skill in the art that, it can
To make various changes to it in the form and details, without departing from of the invention defined by the appended claims
Spirit and scope.
Claims (7)
1. the method for treating ulcerative colitis with natural sericin, which is characterized in that include the following steps：
（1）Sericin is extracted with the method for high temperature alkaline degradation, after purification, freeze-drying obtains sericin；
（2）It will（1）Obtained sericin/sodium alginate soln/CaCl2•2H2O solution mixing systems must be used for ulcerative colitis
（Ulcerative colitis, UC）Silk gum/sodium alginate composite hydrogel for the treatment of；
（3）It will（2）Obtained silk gum/sodium alginate composite hydrogel carries out oral administration gavage processing to suffering from UC mouse, is used for the disease
The treatment of disease.
2. the method according to claim 1 for treating ulcerative colitis with natural sericin, it is characterised in that：It is described
Step（1）The molecular weight of middle sericin is more than 1 KDa.
3. the method according to claim 1 for treating ulcerative colitis with natural sericin, it is characterised in that：It is described
Step（2）The mass ratio of sericin and sodium alginate in middle silk gum/sodium alginate composite hydrogel is 1 ~ 50, ionomer
Agent CaCl2•2H2A concentration of 1 ~ 5 wt% of O solution.
4. the method according to claim 1 for treating ulcerative colitis with natural sericin, it is characterised in that：It is described
Step（3）In the dosage for suffering from UC Mouse oral sericins be 0.1 ~ 5 g/kg.
5. the method according to claim 2 for treating ulcerative colitis with natural sericin, it is characterised in that：It is described
Step（1）The molecular weight of middle sericin is 1 ~ 220 KDa.
6. the method according to claim 3 for treating ulcerative colitis with natural sericin, it is characterised in that：It is described
Step（2）The sericin of middle silk gum/sodium alginate composite hydrogel and the mass ratio of sodium alginate are 100:（10~50）, from
Sub- crosslinking agent CaCl2•2H2A concentration of 1 ~ 2 wt% of O solution.
7. the method according to claim 4 for treating ulcerative colitis with natural sericin, it is characterised in that：It is described
Step（3）In the dosage for suffering from UC Mouse oral sericins be 0.5 g/kg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810721564.2A CN108452291A (en) | 2018-07-04 | 2018-07-04 | The method for treating ulcerative colitis with natural sericin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810721564.2A CN108452291A (en) | 2018-07-04 | 2018-07-04 | The method for treating ulcerative colitis with natural sericin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108452291A true CN108452291A (en) | 2018-08-28 |
Family
ID=63216356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810721564.2A Withdrawn CN108452291A (en) | 2018-07-04 | 2018-07-04 | The method for treating ulcerative colitis with natural sericin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108452291A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109258963A (en) * | 2018-09-18 | 2019-01-25 | 浙江汇能生物股份有限公司 | A kind of calcium polycarbophil stomach floating particle and the application on livestock and poultry |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1913875A (en) * | 2004-04-01 | 2007-02-14 | 希格马托制药工业公司 | Anionic hydrogel matrices with pH dependent modified release as drug carriers |
| CN103313716A (en) * | 2010-11-30 | 2013-09-18 | 瑞瑟医药有限公司 | Topical compositions for preserving or restoring the integrity of mucosae |
| CN105985529A (en) * | 2015-03-05 | 2016-10-05 | 华中科技大学同济医学院附属协和医院 | Sericin-alginate compounded hydrogel and preparation method thereof |
-
2018
- 2018-07-04 CN CN201810721564.2A patent/CN108452291A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1913875A (en) * | 2004-04-01 | 2007-02-14 | 希格马托制药工业公司 | Anionic hydrogel matrices with pH dependent modified release as drug carriers |
| CN103313716A (en) * | 2010-11-30 | 2013-09-18 | 瑞瑟医药有限公司 | Topical compositions for preserving or restoring the integrity of mucosae |
| CN105985529A (en) * | 2015-03-05 | 2016-10-05 | 华中科技大学同济医学院附属协和医院 | Sericin-alginate compounded hydrogel and preparation method thereof |
Non-Patent Citations (5)
| Title |
|---|
| MATRAN 等: "APPLICABILITY OF SERICULTURE IN THE FOOD INDUSTRY AND MEDICINE", 《REVISTA LUCRARI STIINTIFICE》 * |
| OKAZAKI 等: "Consumption of a Resistant Protein, Sericin, Elevates Fecal Immunoglobulin A, Mucins, and Cecal Organic Acids in Rats Fed a High-Fat Diet", 《THE JOURNAL OF NUTRITON》 * |
| 张永锋 等: "葡聚糖硫酸钠致小鼠结肠炎模型的建立与评价", 《深圳中西医结合杂质》 * |
| 彭司勋 主编: "《中国药学年鉴（2008）》", 31 January 2009, 第二军医大学出版社 * |
| 李望: "猴头菌丝体多糖对小鼠溃疡性结肠炎的影响极其抗炎机制研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109258963A (en) * | 2018-09-18 | 2019-01-25 | 浙江汇能生物股份有限公司 | A kind of calcium polycarbophil stomach floating particle and the application on livestock and poultry |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rahimi et al. | Recent developments in natural and synthetic polymeric drug delivery systems used for the treatment of osteoarthritis | |
| Ouyang et al. | Multifunctional hydrogels based on chitosan, hyaluronic acid and other biological macromolecules for the treatment of inflammatory bowel disease: A review | |
| US5102666A (en) | Calcium polycarbophil controlled release composition and method | |
| Arora et al. | Amoxicillin loaded chitosan–alginate polyelectrolyte complex nanoparticles as mucopenetrating delivery system for H. pylori | |
| Salamat-Miller et al. | The use of mucoadhesive polymers in buccal drug delivery | |
| US5110605A (en) | Calcium polycarbophil-alginate controlled release composition and method | |
| EP0952822B1 (en) | Chitosan-gelatin a microparticles | |
| US6656925B2 (en) | Composition and method of treating arthritis | |
| CN104958251A (en) | Preparation method of hyaluronic acid nanogel | |
| EP0497956B1 (en) | Controlled release formulations | |
| Abourehab et al. | Chondroitin sulfate-based composites: a tour d’horizon of their biomedical applications | |
| CN108452291A (en) | The method for treating ulcerative colitis with natural sericin | |
| Sheoran | Buccal drug delivery system: A review | |
| Xu et al. | Microparticles based on alginate/chitosan/casein three‐dimensional system for oral insulin delivery | |
| Qu et al. | Chitosan as a biomaterial for the prevention and treatment of dental caries: antibacterial effect, biomimetic mineralization, and drug delivery | |
| Singh et al. | Chitosan: A novel excipient in pharmaceutical formulation: A review | |
| CN100366288C (en) | Dental ulcerative glue | |
| Morales-Burgos et al. | Polysaccharides in alternative methods for insulin delivery | |
| Li et al. | Chitosan-DNA microparticles as mucosal delivery system: synthesis, characterization and release in vitro | |
| Zhu et al. | Responsively Degradable Nanoarmor‐Assisted Super Resistance and Stable Colonization of Probiotics for Enhanced Inflammation‐Targeted Delivery | |
| US20220226436A1 (en) | Mucoadhesive microgel compositions and methods for using the same | |
| Cui et al. | Current and future outlook of loaded components in hydrogel composites for the treatment of chronic diabetic ulcers | |
| CN110787288A (en) | Medical collagen oral ulcer protective gel and preparation method thereof | |
| CN114983982B (en) | Sustained-release type oral ulcer hydrogel ulcer patch | |
| CN108785496A (en) | A kind of canker sore sustained release pad pasting and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180828 |
|
| WW01 | Invention patent application withdrawn after publication |